Vantage logo

Déjà vu for Aveo and tivozanib

As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.